Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer  

作　　者：Sha Zhu Jin-Ge Zhao Jun-Ru Chen Zhen-Hua Liu Guang-Xi Sun Zhi-Peng Wang Yu-Chao Ni Jin-Dong Dai Peng-Fei Shen Hao Zeng 

机构地区：[1]Department of Urology,Institute of Urology,West China Hospital,Sichuan University,Chengdu 610041,China.

出　　处：《Asian Journal of Andrology》2020年第5期519-525,共7页亚洲男性学杂志（英文版）

摘　　要：Intraductal carcinoma of the prostate(IDC-P)is an aggressive pathological pattern of prostate cancer(PCa).We investigated the association of IDC-P in prostate biopsy(PBx)with several pathological features after radical prostatectomy(RP)and its prognostic value in high-risk PCa.A total of 418 patients with high-risk PCa after RP were included in this study.IDC-P and its architectural patterns were identified according to the 2016 World Health Organization Classification.Chi-squared test and logistic regression were used to investigate the correlation between IDC-P and post-RP pathological features.Kaplan-Meier curves and Cox regression were applied to explore the prognostic value of IDC-P.IDC-P was identified in PBx in 36/418(8.6%)patients.Logistic regression indicated that IDC-P in PBx was independently associated with several pathological features of RP,including Gleason score 8-10(P<0.001),seminal vesicular invasion(P<0.001),and pathological T(pT)3a(P=0.043).Patients with IDC-P in PBx manifested poorer biochemical-free survival(BFS)than those without IDC-P(37.47 months vs not reached,P<0.001).The addition of IDC-P in several prognostic nomograms could improve the predictive accuracy of these tools.We conclude that IDC-P in PBx is positively associated with several aggressive pathological features after RP in high-risk PCa.In addition,IDC-P in PBx could effectively predict the BFS of high-risk PCa patients after RP.

关 键 词：BIOPSY high risk intraductal carcinoma of the prostate PROGNOSIS prostate cancer 

分 类 号：R737.25[医药卫生—肿瘤]